Recent Company News

• 07:55 AM ET Jun 10, 2026
  

  Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

• 09:34 AM ET May 20, 2026
  

  BioMedNewsBreaks -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Eilon Elmalem as Head of Yavne CDMO Facility

• 07:00 AM ET May 20, 2026
  

  Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

• 08:05 AM ET May 15, 2026
  

  Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

• 07:59 AM ET Apr 24, 2026
  

  Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

• 07:10 AM ET Jul 23, 2024
  

  Scinai Immunotherapeutics announces Positive Regulatory Feedback from PEI on path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb ($4.31, 0.00)